Welireg®

Active substance   Belzutifan
Holder MSD Belgium BV/SRL
Status Running
Indication Belzutifan (Welireg®) is indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for VHL associated, localized renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumours (pNET), and for w

Vyvgart

Werkzame stof efgartigimod alfa
Holder Argenx Benelux BV
Status Running
Indication Medical Need Program with Vyvgart 1000 mg solution for subcutaneous injection as monotherapy for adult patients with progressive or relapsing active Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), after prior treatment with immunoglobulins and/or corticosteroids.
<

REMINDER - Marketing stop of Depakine (sodium valproate) 300 mg/5 ml syrup: beware of medication errors

As announced in December 2024, Sanofi Belgium has decided to stop marketing Depakine 300 mg/5 ml syrup as of 28 April 2025. Depakine's other oral liquid formulation, the 300 mg/ml oral solution, will remain available in Belgium. As the latter is more concentrated than the syrup and dosed with a different device, patients, healthcare professionals and parents need to be informed and prepared to avoid potential medication errors.
Active substance Ribociclib
Holder Novartis Pharma
Status Running
Indication The adjuvant treatment of patients with ribociclib diagnosed with early-stage Hormone Receptor-positive (HR+), Human Epidermal growth factor Receptor 2-negative (HER2─) breast cancer (stages II and III) requiring adjuvant treatment with an endocrine treatment based regimen.
Active substance     Belantamab mafodotin
Holder GlaxoSmithKline Pharmaceuticals S.A./N.V.
Status Running
Indication Belantamab mafodotin is indicated in adults for the treatment of relapsed or refractory multiple myeloma:

Duvyzat

Active substance givinostat
Holder  Italfarmaco S.p.A.
Status Running
Indication Givinostat Compassionate Use Programme (CUP) for treatment of ambulant patients aged 6 years and older with Duchenne Muscular Dystrophy (DMD)
Public documents

Jayprica®

Active substance     pirtobrutinib
Holder S.A. Eli Lilly N.V
Status Running
Indication Pirtobrutinib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have been exposed to a Bruton’s tyrosine kinase (BTK) inhibitor and venetoclax (i.e.

Teplizumab

Active substance Teplizumab
Holder Sanofi Belgium
Status Running
Indication Teplizumab is indicated for the treatment of adult and pediatric patients aged 8 years and older with stage 2 type 1 diabetes to delay the onset of stage 3 type 1 diabetes
Subscribe to